Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

The goal of this study is to assess if patients can be retained on long-term vadadustat therapy (and thus potentially benefit from the favorable safety profile) by incorporating a phased transition from Epogen to three times per week vadadustat (TIW-V), reducing the likelihood of GI intolerance through use of a lower vadadustat starting dose, and also reducing or eliminating the initial reduction in hemoglobin through the maintenance of low dose Epogen until target hemoglobin stability is achieved on a tolerable dose of TIW-V.

NCT Number	NCT07565701
Lead Sponsor	Geoff Block Collaborators: Akebia Therapeutics
Conditions	Anemia Associated With Chronic Kidney Disease
Enrollment	100 participants
Start Date	2026-04
Primary Completion	2027-04 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-04